SAN DIEGO, CA — November 4, 2025 — Leads & Copy —
Cardiff Oncology Inc. (Nasdaq: CRDF) announced that company management will participate in two upcoming investor conferences in November 2025. Mark Erlander, PhD (CEO) will be a presenter at both conferences. The first is the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on 11/11/2025 at 9:30 AM ET with a format of Fireside Chat and 1×1 Meetings. The second is the Stifel 2025 Healthcare Conference on 11/12/2025 at 9:20 AM ET with a format of Corporate Presentation and 1×1 Meetings. Interested parties can register for and access the live webcast for the conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company’s lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company’s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Candice Masse
Astr Partners
candice.masse@astrpartners.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
Source: Cardiff Oncology, Inc.
